Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 Meeting
(WorldNews Health)

Oral rigosertib as a single agent demonstrates activity in a Phase 2 trial for lower-risk MDS 32% of 62 evaluable patients, and 44% of patients receiving optimal dosing, achieved transfusion independence New data on the molecular basis of the combination therapy with rigosertib and azacitidine in epigenetic studies in patient derived stem cells NEWTOWN, Pa., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, delivered two poster presentations highlighting drug activity and the mechanism of action of rigosertib in Myelodysplastic Syndromes during...